The structural profiles are close, with Alnylam Pharmaceuticals carrying a narrow edge on growth. The remaining gap is narrow enough that the comparison remains open to different readings. In the market, argenx SE carries the stronger setup — intact trend against Alnylam Pharmaceuticals's broken trend. That leaves a split case: the structural lead stays with Alnylam Pharmaceuticals, but the market is not currently confirming it.
The comparison is based on similar long-term financial trajectories, not sector labels. Peer scores are normalised within each company's primary universe (ALNY: Nasdaq 100, ARGX.BR: STOXX 600).
The comparison is mainly decided in growth, with the rest of the profile carrying less weight.
Both operate in: Biotechnology
This comparison is based on industry proximity, not on functional trajectory similarity. ALNY and ARGX.BR share the same industry classification.
For a similarity-based comparison, see how Alnylam Pharmaceuticals and argenx SE each position within their functional peer groups in AssetNext.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
The clearest separation appears in growth.
Left means cheaper relative valuation. Higher means stronger structure.
The setup stays mixed because structure and the price setup do not align cleanly in one direction.
Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.
Where ALNY and ARGX.BR each sit in their own 5-year price and valuation history.
Describes historical entry positioning only. Descriptive — not investment advice.
Revenue growth reinforces the category-level growth lead.
On the market side, argenx SE carries the stronger trend while Alnylam Pharmaceuticals's trend has broken — the market setup does not confirm the structural advantage.
The main read on growth is clearer than the broader score gap.
Break down the ALNY vs ARGX.BR comparison across all dimensions with the full interactive tool.
Explore how ALNY and ARGX.BR each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.